| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Glyn Lewis | Q5572854 |
| Nicky J. Welton | Q40080704 | ||
| Helen Baxter | Q64496080 | ||
| David Kessler | Q90209750 | ||
| Rachel Churchill | Q92203672 | ||
| P2093 | author name string | William Hollingworth | |
| Petros Skapinakis | |||
| Naomi A Fineberg | |||
| Deborah M Caldwell | |||
| Paul Salkovskis | |||
| Peter Bryden | |||
| P2860 | cites work | Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder | Q22306279 |
| Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD) | Q24242402 | ||
| Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD) | Q24245272 | ||
| The effects of psychotherapy for adult depression are overestimated: a meta-analysis of study quality and effect size | Q24273208 | ||
| A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder | Q28255942 | ||
| The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability | Q28272890 | ||
| Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. | Q48320512 | ||
| Treatment of obsessions: a randomized controlled trial. | Q50717139 | ||
| Controlled trial of exposure and response prevention in obsessive-compulsive disorder. | Q51101421 | ||
| Group versus individual cognitive-behavioural treatment for obsessive-compulsive disorder: a controlled trial. | Q51920348 | ||
| Cognitive-behavioral group therapy in obsessive-compulsive disorder: a randomized clinical trial. | Q51948381 | ||
| Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. | Q51952581 | ||
| Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder: a single-blind study. | Q51999823 | ||
| Cognitive-behavioral treatment of obsessive thoughts: a controlled study. | Q52001219 | ||
| Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. | Q52009100 | ||
| Obsessional-compulsive problems: a cognitive-behavioural analysis. | Q53772537 | ||
| Cognitive behaviour therapy and medication in the treatment of obsessive-compulsive disorder | Q56405919 | ||
| Escitalopram in obsessive–compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study | Q56909849 | ||
| Cognitive therapy with obsessive-compulsive disorder: A comparative evaluation | Q60630310 | ||
| Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder | Q28373711 | ||
| Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder | Q32114341 | ||
| Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder | Q33926476 | ||
| Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study | Q33962661 | ||
| The psychological treatment of obsessive-compulsive disorder | Q33997594 | ||
| Simultaneous comparison of multiple treatments: combining direct and indirect evidence. | Q34081552 | ||
| Evidence-based pharmacotherapy of obsessive-compulsive disorder | Q34245428 | ||
| A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder | Q34277538 | ||
| Tocolytic therapy for preterm delivery: systematic review and network meta-analysis | Q34304826 | ||
| Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators | Q34404992 | ||
| Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis. | Q34441802 | ||
| Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study | Q34521893 | ||
| Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder | Q34639772 | ||
| A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. | Q34721352 | ||
| Internet-based cognitive behaviour therapy for obsessive-compulsive disorder: a randomized controlled trial | Q36214868 | ||
| The descriptive epidemiology of obsessive-compulsive disorder. | Q36367999 | ||
| The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons | Q36930878 | ||
| Mortality Among Persons With Obsessive-Compulsive Disorder in Denmark. | Q37371924 | ||
| A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder | Q37623353 | ||
| Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial | Q37639264 | ||
| Quality of life in obsessive compulsive disorder | Q38070934 | ||
| Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review | Q40553095 | ||
| A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory | Q41197878 | ||
| Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo | Q41259841 | ||
| Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials | Q41822229 | ||
| Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. | Q42282457 | ||
| Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. | Q42284053 | ||
| Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials | Q43102818 | ||
| Tricyclic antidepressants in obsessive-compulsive disorder: antiobsessional or antidepressant agents? II. | Q43625506 | ||
| Behavior therapy for obsessive-compulsive disorder guided by a computer or by a clinician compared with relaxation as a control | Q43902570 | ||
| Multivariate meta-analysis of controlled drug studies for obsessive-compulsive disorder | Q43990367 | ||
| A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. | Q44488825 | ||
| Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine | Q44662798 | ||
| St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study | Q44996490 | ||
| Paroxetine in the treatment of obsessive-compulsive disorder: randomized, double-blind, placebo-controlled study in Japanese patients | Q45009930 | ||
| A comparison of behavioral group therapy and individual behavior therapy in treating obsessive-compulsive disorder | Q46339879 | ||
| Individual versus group cognitive-behavioral treatment for obsessive-compulsive disorder: a controlled pilot study. | Q46348188 | ||
| A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine | Q46641387 | ||
| Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled study | Q47725635 | ||
| Treatment-as-usual (TAU) is anything but usual: a meta-analysis of CBT versus TAU for anxiety and depression | Q47755663 | ||
| Cognitive therapy vs exposure in vivo in the treatment of obsessive-compulsives | Q60630319 | ||
| Clomipramine in the treatment of patients with obsessive-compulsive disorder. The Clomipramine Collaborative Study Group | Q67961275 | ||
| Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo | Q68519551 | ||
| Clomipramine and imipramine in obsessive-compulsive disorder | Q69890635 | ||
| Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis | Q70171250 | ||
| Fluvoxamine treatment of obsessive-compulsive disorder | Q70368813 | ||
| Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison | Q71216972 | ||
| Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial | Q71389924 | ||
| Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder | Q71496136 | ||
| Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder | Q72249909 | ||
| Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup | Q72321075 | ||
| A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group | Q72909489 | ||
| A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder | Q73567968 | ||
| Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder | Q73671574 | ||
| Cognitive versus behavior therapy in the group treatment of obsessive-compulsive disorder | Q73976821 | ||
| A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive compulsive disorder | Q74615142 | ||
| Danger ideation reduction therapy (DIRT) for obsessive-compulsive washers. A controlled trial | Q77136871 | ||
| Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study | Q77601192 | ||
| Establishing Specificity in Psychotherapy: A Meta-Analysis of Structural Equivalence of Placebo Controls | Q79300352 | ||
| Treatment of obsessive-compulsive disorder: cognitive behavior therapy vs. exposure and response prevention | Q81780707 | ||
| A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder | Q84446951 | ||
| Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial | Q84929683 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | meta-analysis | Q815382 |
| pharmacology | Q128406 | ||
| psychotropic drug | Q12830468 | ||
| obsessive-compulsive disorder | Q178190 | ||
| psychotherapy | Q183257 | ||
| systematic review | Q1504425 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 730-739 | |
| P577 | publication date | 2016-06-16 | |
| 2016-08-01 | |||
| P1433 | published in | The Lancet Psychiatry | Q27118886 |
| P1476 | title | Pharmacological and psychotherapeutic interventions for management of obsessive-compulsive disorder in adults: a systematic review and network meta-analysis | |
| P478 | volume | 3 |
| Q64072792 | A Randomized Trial Directly Comparing Ventral Capsule and Anteromedial Subthalamic Nucleus Stimulation in Obsessive-Compulsive Disorder: Clinical and Imaging Evidence for Dissociable Effects |
| Q53435211 | A case report of schizoaffective disorder with ritualistic behaviors and catatonic stupor: successful treatment by risperidone and modified electroconvulsive therapy. |
| Q94471960 | A scoping review of network meta-analyses assessing the efficacy and safety of complementary and alternative medicine interventions |
| Q89222798 | Acceptability, Feasibility, and Effectiveness of Internet-Based Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder in New York |
| Q61809178 | Antipsychotic augmentation in the treatment of obsessive-compulsive disorder |
| Q57200350 | Assessing the effectiveness of pharmacotherapy for obsessive-compulsive disorder |
| Q88651390 | Assessing the effectiveness of pharmacotherapy for obsessive-compulsive disorder - Author's reply |
| Q90435436 | Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review |
| Q89702242 | Clinical Practice Guidelines for Cognitive-Behavioral Therapies in Anxiety Disorders and Obsessive-Compulsive and Related Disorders |
| Q37643043 | Clinical practice guidelines for Obsessive-Compulsive Disorder |
| Q92536269 | Deep Brain Stimulation for Refractory Obsessive-Compulsive Disorder: Towards an Individualized Approach |
| Q91745054 | Development and psychometric evaluation of the Mandarin Chinese version of the Yale-Brown Obsessive-Compulsive Scale - Second Edition |
| Q41348812 | Divergent Structural Responses to Pharmacological Interventions in Orbitofronto-Striato-Thalamic and Premotor Circuits in Obsessive-Compulsive Disorder. |
| Q88094501 | Dysfunction by Disclosure? Stereotype Threat as a Source of Secondary Neurocognitive Malperformance in Obsessive-Compulsive Disorder |
| Q88618983 | Evolution of gamma knife capsulotomy for intractable obsessive-compulsive disorder |
| Q94593062 | How to manage obsessive-compulsive disorder (OCD) under COVID-19: A clinician's guide from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS) and the Obsessive-Compulsive and Related Disorders Research Network (OCRN) of the |
| Q47652754 | Is cognitive-behavioural therapy more effective than relaxation therapy in the treatment of anxiety disorders? A meta-analysis. |
| Q48016660 | Mapping Compulsivity in the DSM-5 Obsessive Compulsive and Related Disorders: Cognitive Domains, Neural Circuitry, and Treatment |
| Q97418393 | Metacognitive Training for Obsessive-Compulsive Disorder: a study protocol for a randomized controlled trial |
| Q47192459 | Moderators in psychotherapy meta-analysis. |
| Q88461659 | Network meta-analyses and treatment recommendations for obsessive-compulsive disorder |
| Q47924421 | Network meta-analyses and treatment recommendations for obsessive-compulsive disorder - Authors' reply |
| Q53811851 | Network meta-analyses and treatment recommendations for obsessive-compulsive disorder. |
| Q49415413 | Obsessive Compulsive and Related Disorders: From the Biological Basis to a Rational Pharmacological Treatment |
| Q92353027 | Obsessive-compulsive disorder |
| Q100749189 | Obsessive-compulsive disorder-contamination fears, features and treatment: Novel smartphone therapies in light of global mental health and pandemics (COVID-19) |
| Q59128333 | Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the |
| Q46640641 | Relationships between obsessive-compulsive disorder, depression and functioning before and after exposure and response prevention therapy |
| Q50048677 | Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. |
| Q90717813 | Self-compassion and emotion regulation difficulties in obsessive-compulsive disorder |
| Q89671124 | Serious negative consequences associated with exposure and response prevention for obsessive-compulsive disorder: A survey of therapist attitudes and experiences |
| Q47653707 | Sleep disturbances in treatment-seeking OCD-patients: Changes after concentrated exposure treatment |
| Q91602743 | Symptom dimensions in obsessive-compulsive disorder as predictors of neurobiology and treatment response |
| Q91707053 | The Neuronal Glutamate Transporter EAAT3 in Obsessive-Compulsive Disorder |
| Q58591839 | The Stuck Song Syndrome: A Case of Musical Obsessions |
| Q38968055 | The optimal target for acute glycemic control in critically ill patients: a network meta-analysis |
| Q54968644 | Three-Week Inpatient Treatment of Obsessive-Compulsive Disorder: A 6-Month Follow-Up Study. |
| Q60641765 | Treatments used for obsessive-compulsive disorder-An international perspective |
Search more.